Lör 20 jul / År 42 / Nr 3 2024

Cancer Diagnostics and Regenerative Medicine at the next level

Cline Scientific AB is a Gothenburg-based company with a very interesting history and an even more interesting future. The initial mission and business concept were based on a method to produce nanoscale surface gradients, developed at Gothenburg University and Chalmers University of Technology.

Cell research plays a powerful role in the life sciences, whether it is as a tool for producing biological drugs, as the basis of cell-based therapeutics, or to understand the basis of cancer metastasis. Today, Cline is a leading commercial developer of advanced cancer diagnostics and regenerative medicine treatments based on cell therapy.

Addressing the major challenge in cancer diagnostics
There is a major challenge in today’s cancer diagnostics, namely that there are no reliable methods for identifying the risk of metastases spreading in earlier stages. This is a need which Cline seeks to meet with the help of nanotechnology and cell therapy. The first clinical trials have begun with cultured cells and are now being followed by tests on human biopsies.
“Our technology provides a predictive indicator of metastasis. We are able to use and adapt nanoscale surface engineering to actually map the migration of cancerous cells, which is something that has never been done before. Our aim is to offer a complete cancer diagnostic tool based on this technology within three years”, says Patrik Sundh, CEO and co-founder of Cline Scientific.

Regenerative medicine is not science fiction
As mentioned before, Cline has two main applications for its stem cell technology; cancer diagnostics and regenerative medicine based on recreating stem cells.
Although researchers have been able to culture stem cells for twenty years or more, they have up until now not been able to create cells that can be planted safely into humans. That is because these differentiated cell populations are often not homogenous and there can still be pluripotent cells able to divide uncontrollably and form teratoma, a form of cancer, if implanted in patients.
Researchers at Cline have succeeded in circumventing the problem, and have proven that regenerative medicine treatments, where cells and cellular functions are completely regrown and thus restored, is everything but science fiction.
“Within five years, there may be a full-scale operational treatment in regenerative medicine, based on our research here at Cline followed by a successful project acquisition by a major player. We are about to enter clinical phase I in our stem cell therapy project, and assuming the results turn out as expected, we will then go ahead with the sale of this project”, says Patrik Sundh.